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Background: Autoimmune thyroid disease is a prevailing autoimmune disorder, 
however the functional and clinical roles of antithyroid antibodies have not been fully 
elucidated. 
Objectives: To compare antithyroid antibodies and thyroid function parameters 
between two points in time of follow-up and to identify possible relations between 
antithyroid antibodies and thyroid function parameters, in Hashimoto’s thyroidits. 
Patients and Methods: In this retrospective observational study, we studied a database 
comprising 346 patients with Hashimoto’s thyroiditis assisted at Hospital de Santa 
Maria – Centro Hospitalar Universitário Lisboa Norte, from 2009 ± 6 to 2014 ± 3. 
Statistical data analysis was conducted to detect differences in thyroid hormones and 
antibodies in serum at two different points in time (first visit and last visit of follow-up) 
and to infer from correlations between antithyroid antibodies and thyroid function tests. 
Results: There was a significant reduction of TSH, T3, T4 and TPOAb, and a 
significant increase of fT4 between visits. Significant modest positive correlations 
between TPOAb and TgAb levels, TPOAb and TSH levels and TPOAb and fT4 levels 
were found at the first visit. A significant weak negative correlation between TgAb and 
Tg levels was reported for both visits. We identified subsets of patients who 
preferentially produce TPOAb or TgAb, and those who had positive Tg despite positive 
TgAb. 
Conclusion: The follow-up change we observed in antithyroid antibodies and thyroid 
function shows us that Hashimoto’s thyroiditis is not an immutable disease. The 
correlation between TPOAb and fT4 and TSH might suggest this antibody’s importance 
in Hashimoto’s thyroiditis pathogenesis. The difference in TPOAb and TgAb 
expression in distinct patient subsets could reflect the evolution of Hashimoto’s 
thyroiditis, a random phenomenon or a different clinical situation altogether. 
Keywords: antithyroid antibodies; autoimmune thyroid disease; Hashimoto’s 
thyroiditis; anti-thyroid peroxidase antibody; anti-thyroglobulin antibody. 
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Introdução: A doença tiroideia autoimune é uma doença autoimune prevalente, 
contudo os papéis funcional e clínico dos anticorpos anti-tiroideus permanecem por 
esclarecer. 
Objetivos: Comparar os anticorpos antitiroideus e parâmetros de função tiroideia em 
dois pontos do tempo distintos do seguimento e identificar possíveis correlações entre 
os anticorpos anti-tiroideus e parâmetros de função tiroideia, na tiroidite de Hashimoto. 
Doentes e Métodos: Neste estudo retrospetivo observacional, estudámos uma base de 
dados de 346 doentes com tiroidite de Hashimoto seguidos no Hospital de Santa Maria 
– Centro Hospitalar Universitário Lisboa Norte, de 2009 ± 6 a 2014 ± 3. A análise 
estatística foi realizada para detetar diferenças entre as hormonas e anticorpos tiroideus 
séricos nas primeira e última consultas do seguimento e para inferir sobre correlações 
entre as hormonas e anticorpos tiroideus. 
Resultados: Verificou-se uma redução significativa de TSH, T3, T4 e TPOAb, e um 
aumento significativo de fT4 entre consultas. Correlações modestas e positivas entre 
TPOAb e TgAb, TPOAb e TSH, e TPOAb e fT4 foram descritas na primeira consulta. 
Uma correlação modesta negativa entre TgAb e Tg foi documentada nas duas consultas. 
Identificámos subgrupos de doentes que produziam preferencialmente TPOAb ou 
TgAb, e aqueles que tinham medições positivas de Tg apesar de medições positivas de 
TgAb. 
Conclusão: As alterações nos anticorpos anti-tiroideus e função tiroideia observadas no 
seguimento destes doentes mostra que a tiroidite de Hashimoto não é uma doença 
imutável. A correlação entre TPOAb e fT4 e TSH poderá sugerir a importância deste 
anticorpo na tiroidite de Hashimoto. As diferenças na expressão de TPOAb e TgAb em 
diferentes subgrupos de doentes poderão refletir a evolução natural da tiroidite de 
Hashimoto, um fenómeno aleatório ou uma situação clínica distinta. 
Palavras-Chave: anticorpos anti-tiroideus; doença tiroideia autoimune; tiroidite de 
Hashimoto; anticorpo anti-peroxidase tiroideia; anticorpo anti-tiroglobulina. 
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fT4 Free thyroxine 
fT41 Free thyroxine at the first visit 
fT4L Free thyroxine at the last visit 
HAb Heterophile antibodies 
NIS  Sodium/iodide-symporter 
NS Not significant 
T3 Total triiodothyronine 
T31 Total triiodothyronine at the first visit 
T3L Total triiodothyronine at the last visit 
T4 Total thyroxine 
T41 Total thyroxine at the first visit 
T4L Total thyroxine at the last visit 
TSH Thyroid-stimulating hormone 
TSH1 Thyroid-stimulating hormone at the first visit 
TSHL Thyroid-stimulating hormone at the last visit 
TSH-R Thyroid-stimulating hormone receptor 
Tg Thyroglobulin 
Tg1 Thyroglobulin at the first visit 
Tg Thyroglobulin at the last visit 
TgAb Anti-thyroglobulin antibodies 
TgAb1 Anti-thyroglobulin antibodies at the first visit 
TgAbL Anti-thyroglobulin antibodies at the last visit 
TPO Thyroid peroxidase 
TPOAb Anti-thyroid peroxidase antibodies 
TPOAb1 Anti-thyroid peroxidase antibodies at the first visit 
TPOAbL Anti-thyroid peroxidase antibodies at the last visit 







 Autoimmune thyroid diseases, including Hashimoto’s thyroiditis and Graves’ 
disease, remain the most frequent autoimmune diseases in the adult population [1], [2]. 
There is a female preponderance in all types of autoimmune thyroid disease [1], [2], 
except for IgG4-related thyroiditis [3]. 
 Both Hashimoto’s thyroiditis and Graves’ disease feature diffuse lymphocytic 
infiltration of the thyroid gland and the presence of antibodies against thyroid 
autoantigens, most commonly thyroid peroxidase (TPO), thyroglobulin (Tg) and 
thyroid-stimulating hormone (TSH) receptor [4]. Rarely, antibodies against other 
thyroid-specific antigens such as triiodothyronine (T3), thyroxine (T4), sodium/iodide-
symporter (NIS), pendrin, carbonic anhydrase 2 and megalin have also been identified 
[4]–[6]. 
 With the exception of TSH receptor antibodies (TRAb) [7], thyroid 
autoantibodies, although useful for the diagnosis of autoimmune thyroid disease, are 
assumed to lack physiological or clinical relevance and may be determined only once, at 
the first visit [8]–[10]. 
 André Gide, a french writer, stated that we call experience always repeating the 
same mistakes. Therefore, we decided to challenge old common assumptions by 
exploring data from our patients with Hashimoto’s thyroiditis. 
 We will summarize the current clinical relevance and utility of antithyroid 
antibodies in thyroid disease. As a retrospective observational study, this paper will 
focus on examining the interrelationship of antithyroid antibodies and their influence on 
thyroid hormones, as well as the long-term evolution of antithyroid antibodies and 
thyroid function in Hashimoto’s thyroiditis. 
 
Hashimoto’s Thyroiditis 
 Hashimoto’s thyroiditis is an autoimmune condition affecting the thyroid gland, 
resulting from the combination of genetic susceptibility, conferred by a number of 
immune-related and thyroid-specific genes, with multiple environmental and existential 
factors [11]–[13]. 
 Both cellular and humoral immunity play a role in Hashimoto’s thyroiditis 
pathogenesis. As Ajjan et al. eloquently described, altered activity of T regulatory cells, 
increased function of follicular helper T cells coupled with release of DNA fragments 
by cell death and deranged microRNA profile contribute to a breakdown of T cell 
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tolerance. The subsequent initiation and perpetuation of the autoimmune process results 
in thyroid infiltration by T and B cells, with predominating Th1 phenotype. These 
lymphocytes are responsible for thyroid cell injury through: (a) CD8+ mediated 
cytotoxicity and apoptosis; (b) production of cytokines, which cause disruption of 
thyroid hormone synthesis, induce the expression of other proinflammatory molecules 
by the thyroid cells themselves (including MHC II molecules), promote oxidative stress, 
compromise thyroid follicular cell integrity and further stimulate T and B cells; and (c) 
antibody production [11], [14]. 
 Antithyroid antibodies are produced by intrathyroidal B cells and, to a lesser 
extent, in cervical lymph nodes and the bone marrow [15], [16]. Their role in thyroid 
autoimmunity induced damage to the thyroid gland is unclear. Intrathyroidal 
complement fixation by thyroid antibodies occurs but might not lyse cells [17]. 
However, antithyroid antibodies may play a secondary amplifying role in the 
autoimmune response. By sublethal complement attack, antithyroid antibodies lead to 
impaired TSH responsiveness, release of pro-inflammatory molecules and oxidative 
cells [18], [19]. Antibody-dependent cell-mediated cytotoxicity carried out by natural 
killer cells and monocytes has been demonstrated in vitro [20]. Transplacental passage 
of maternal TPOAb or TgAb does not affect the fetal thyroid, which suggests that a T 
cell effector is required to initiate autoimmune damage to the thyroid [21]. 
 Most forms of Hashimoto’s thyroiditis ultimately evolve into hypothyroidism, 
although patients can be euthyroid. The progressive destruction and atrophy of the 
thyroid follicular unit results in the loss of production and secretion of thyroid hormones 
and a compensatory rise in TSH [22]. 
 
Antithyroid Peroxidase Antibodies 
 Anti-thyroid peroxidase antibodies (TPOAb) are polyclonal immunoglobulins 
directed against thyroid peroxidase, belonging to any subclass of IgG class or, rarely, 
IgA class [23]. Thyroid peroxidase is a key thyroid enzyme localized in the apical 
membrane of thyrocytes, responsible for catalyzing iodine oxidation, Tg organification 
and intrachain coupling of iodotyrosines to generate T4 and T3 [24]. 
 TPOAb are found in 5–20% of the general population. The kind of TPOAb found 
on subjects without thyroid dysfunction seems to differ from TPOAb found patients 
with thyroid dysfunction, once they do not block TPO activity or interfere with actions 
of TPOAb found in autoimmune thyroid disease [25], [26]. The significance of TPOAb 
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in euthyroid individuals is uncertain [27], [28]. TPO might be an antigen for low 
amounts of naturally occurring autoantibodies, without pathogenic consequences [29]. 
 Detection of TPOAb occurs in 90–95% of autoimmune thyroid disease patients, 
nearly 100% of Hashimoto’s thyroiditis patients and 80% of Graves’ disease patients 
[4], [30]. In contrast with TgAb, TPOAb of autoimmune thyroid disease fix 
complement, promote cell-mediated cytotoxicity and C3 complement-mediated 
cytotoxicity, contributing to thyrocyte damage, and competitively inhibit TPO’s 
enzymatic activity [20], [26], [31]–[34]. 
 These differences in activity of TPOAb associated with thyroid dysfunction and 
TPOAb not associated with thyroid dysfunction might be explained, at least in part, by 
different IgG subclass distribution. TPOAb from serum of patients’ with thyroid 
dysfunction patients are predominantly IgG1, whilst TPOAb from serum of patients’ 
without thyroid dysfunction are predominantly IgG4 [35]. Additionally, their 
pathogenic potential might be linked to which TPO epitope they are binding to [36]. 
 
Clinical Utility of Antithyroid Peroxidase Antibodies 
1. Hashimoto’s Thyroiditis and Hypothyroidism 
 TPOAb are a more sensitive serological marker for thyroid autoimmunity, than 
TgAb [25], [37]. Only positive TPOAb were found to correlate with thyroid dysfunction 
and hypothyroidism [25]. There is also a with a significant correlation between the 
degree of lymphocytic thyroiditis and TPOAb titers [38]. 
 TPOAb measurement participates in the investigation of hypothyroidism, by 
establishing Hashimoto’s thyroiditis as the underlying cause [10], [39].  
 In the Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored 
by the American Association of Clinical Endocrinologists and the American Thyroid 
Association, TPOAb status assessment is recommended when nodular thyroid disease or 
diffuse goiter are suspected to be secondary to autoimmune thyroid disease. There are 
no recommendations for further evaluations [10]. 
 In the NICE guideline for thyroid disease: assessment and management, 
measuring TPOAb for adults with confirmed primary hypothyroidism is recommended. 






2. Subclinical Hypothyroidism 
 Elevated TPOAb titers in subclinical hypothyroidism predict progression to overt 
hypothyroidism, at an annual progression rate of 4.3% with positive TPOAb versus 
2.6% with negative TPOAb [27], [40]. 
 TPOAb assessment is to be considered in the setting of subclinical 
hypothyroidism [10], [39], [41]. The NICE guidelines and the 2013 ETA Guideline: 
Management of Subclinical Hypothyroidism do not indicate repetition of TPOAb 
measurement in subclinical hypothyroidism [39], [41]. 
 Elevated TPOAb levels in patients with subclinical hypothyroidism may warrant 




 Anti-thyroglobulin antibodies are 330-kDa polyclonal immunoglobulins directed 
against thyroglobulin, belonging to the IgG class or, less often, IgA or IgM class [4], 
[42]–[44]. Thyroglobulin is a 660-kDa homodimeric glycoprotein stored as colloid in 
the follicular lumen, representing 75-80% of total thyroid protein, whose physiologic 
roles include supplying a template for thyroid hormone biosynthesis, storage of iodine, 
and modulation of thyroid follicular function [45]–[47]. Out of 40 identified epitopes in 
the Tg molecule, only 6 are immunogenic [48]. 
 Abnormal production TgAb associates with higher serum Tg concentration, 
higher iodine content of Tg, conformational changes in Tg, and supernormal TSH levels 
[49]. 
 TgAb prevalence is higher in women, with advancing age and iodine 
supplementation of iodine deficient areas [25], [50]–[52]. 
 Albeit primarily found as part of the pathogenic mechanisms integrating thyroid 
autoimmunity [11], TgAb are also present in 10% of the general population without any 
evidence of thyroid disease [25], [53], [54]. 
 Serum TgAb is a conventional marker for thyroid autoimmunity, being detected in 
60% of patients with autoimmune thyroid disease, 60–80% of Hashimoto’s thyroiditis 
patients and 50–60% of Graves’ disease patients [4], [55]. 
 The patterns of TgAb differ between autoimmune thyroid disease patients and 
non-autoimmune thyroid disease patients [48]. 
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 Their functional role is unclear. TgAb are not complement fixing, because Tg 
epitopes are too widely spaced to allow cross-linking [42]. TgAb do not cause thyroid 
cell destruction [42]. 
 
Clinical Utility of Antithyroglobulin Antibodies 
1. Autoimmune Thyroid Disease 
 TgAb are less sensitive thyroid autoimmunity biomarkers, when compared with 
TPOAb and TRAb [56]. In the absence of TPOAb, TgAb are not associated with 
thyroid dysfunction [25]. 
 Measurement of TgAb is not necessary for the diagnosis of thyroid autoimmune 
disease, including Hashimoto’s thyroiditis [10], [39]. 
2. Differentiated Thyroid Cancer 
 TgAb holds its primary value in the context of differentiated thyroid cancer. They 
are found in 25–30% of patients with differentiated thyroid cancer, which compounds a 
two-fold higher rate than that of the general population [54], [57]. 
 The mechanisms of TgAb production in the context of thyroid cancer may stem 
from an underlying autoimmune thyroiditis or from an immunologic response to 
thyroglobulin with increased immunogenicity, generated by tumor thyroid cells [48], 
[58]–[61]. In fact, altered production and secretion of Tg by tumor cells has been 
observed [62]–[64]. The biosynthetic process of Tg could potentially become 
unregulated in thyroid tumour cells, resulting in unpredictable changes in the spatial 
conformation and tertiary structure of Tg, leading to exposure or masking of epitopes 
and, thus, different Tg immunoreactivity [60], [65], [66]. Different epitope patterns of 
TgAb described in autoimmune thyroiditis and differentiated thyroid cells support the 
hypothesis of a dual mechanism [67]. 
2.1 Postoperative Role of Anti-Thyroglobulin Antibodies in Differentiated Thyroid 
Cancer 
 TgAb interference renders serum Tg measurements unreliable, once it can lead to 
spuriously low or high results in any Tg assay [54], [68]–[73]. Of note, postoperative Tg 
is an instrumental biochemical marker to ascertain the effectiveness of treatment for 
differentiated thyroid cancer and for long-term surveillance of residual or recurrent 
disease, following total thyroidectomy and radioiodine remnant ablation [56], [64], 
[74]–[76]. Thus, TgAb and Tg must be measured concurrently in the same sample, with 
interpretation of the Tg level accordingly [56], [74], [77]. Moreover, it is essential that 
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the presence of TgAb be assessed everytime Tg is measured, once the TgAb status may 
change overtime [74], [78]. 
 As stated above, the main clinical utility of TgAb is to ensure the reliability of the 
serum Tg in the follow-up of differentiated thyroid cancer. For patients with positive 
TgAb, TgAb has evolved as a surrogate marker for the follow-up of differentiated 
thyroid cancer [64], [79]. 
 TgAb concentrations respond to changes in the mass of Tg-secreting thyroid 
tissue [80]. Hence, the TgAb trend, defined by the sequential changes in TgAb titers, 
proves more robust than the qualitative or single quantitative value of TgAb for 
predicting disease prognosis [81]–[83]. Declining TgAb levels indicate a lower risk of 
recurrent or persistent disease [83]–[86]. Stable TgAb levels could stem from continued 
Tg antigen secretion by small volume of remnant thyroid tissue or tumoral micro-foci, 
as well as long-lived plasma cells [87], [88]. Stable but higher concentrations of TgAb 
reflect a higher recurrence risk, than lower concentrations of TgAb [84]. A sustained 
rising trend or permanent new emergence of TgAb, on the other hand, is suggestive of 
persistent or recurrent disease [79], [83], [89]–[93]. 
 Furthermore, an unsuccessful radioablation correlates with higher post- 
radioablation TgAb values [94], [95]. 
 Finally, serum TgAb interference in FNA-Tg from suspicious lymph nodes of 
differentiated thyroid cancer patients is controversial, once it has been reported to 
happen in some studies [96]–[99], but not in others [100]–[102]. 
2.2 Preoperative Role of Anti-Thyroglobulin Antibodies in Differentiated Thyroid 
Cancer 
 High preoperative TgAb levels weakly predict thyroid cancer in thyroid nodules 
[42], [103]–[105]. A systematic review and meta‐analysis by Xiao et al. established 
sensitivity of 16.04% and specificity of 90.67% of TgAb for the diagnosis of thyroid 
cancer [106]. Regardless, the ATA guidelines recommend against measurement of 








PATIENTS AND METHODS 
Patients 
In the present retrospective observational study, we examined a database 
comprising 346 patients diagnosed with Hashimoto’s thyroiditis, who were assisted at 
the outpatient endocrine clinic of a public central university hospital in Lisbon (Hospital 
de Santa Maria – Centro Hospitalar Universitário Lisboa Norte; HSM-CHULN), from 
2009 ± 6 to 2014 ± 3. All patients provided a written informed consent concerning the 
authorization for clinical data use in future research studies, after approval by our 
hospital’s Ethics Committee. 
The diagnosis of Hashimoto’s thyroiditis was defined as TPOAb or TgAb 
positivity and absence of hyperthyroidism. 
The following variables, retrieved anonymously from patient’s clinical records 
and included in a specifically designed database, were analyzed: (1) sex; (2) age (in 
years); (3) diagnosis; (4) time since diagnosis (in years); (5) time of follow up (in 
years); (6) TSH, T3, T4, fT4, Tg, TPOAb, TgAb and TPOAb/TgAb ratio at the first and 
last visits; (7) presence of thyroid dysfunction at the first visit (defined as TSH outside 
the normal reference range); (8) levothyroxine therapy at the first and last visits. 
Blood samples were collected in the morning (8 – 10h) at the Clinical Pathology 
Department, after an overnight fast. All thyroid function tests and thyroid antibodies 
related variables were assessed by commercially available standard chemiluminescent 
immunoassays, at the Clinical Pathology Department. The department complies with 
the standards of practice and is a registered and certified facility. 
The normal reference ranges considered for these variables are presented in 
Table 1. 
 
Table 1. Reference range intervals for thyroid variables 
TSH 0.35 - 5.50 μU/mL 
T3 60 - 180 ng/dL 
T4 4.5 - 11 μg/dL 
fT4 0.9 - 1.8 ng/dL 
Tg < 55 ng/mL 
TPOAb < 40 U/mL 





Statistical data analysis was performed using the statistics software program 
IBM SPSS version 26.0 (IBM Corp. Released 2019. IBM SPSS Statistics for Windows, 
Version 26.0. Armonk, NY: IBM Corp.). Limit of significance was set at two-tailed p-
value < 0.05. 
Normality was verified with the Kolmogorov-Smirnov Test. Non-parametric 
tests were used for non-normal distributed variables. Differences between the paired 
first and last visits’ variables were tested with the non-parametric Wilcoxon Signed-
Rank Test. Chi-square test (χ2) was conducted to test differences between TPOAb and 
TgAb positivity in both visits and between visits. Non-parametric Spearman Rank 
Order Regression was conducted to determine the relation between antithyroid 
antibodies (TPOAb and TgAb) and thyroid function tests as well as other clinical 
variables. 
























Study Population Profile 
 Demographic data were analyzed from 346 patients, 90% of which were female (n 
= 310). Most patients were middle aged (51 ± 17 years old at the first visit), with long 
standing disease (8 ± 8 years). Only 24% of patients presented with thyroid dysfunction 
and 49% were under levothyroxine therapy (hence, a total of 73% of patients had 
thyroid dysfunction), at the time of the first visit. At the last visit, after an average 
follow-up of 5 ± 4 years, 9% of patients presented with thyroid dysfunction and 73% 
were under levothyroxine therapy (hence, a total of 82% of patients had thyroid 
dysfunction). Biochemical and serological data of all patients are presented in Table 2 
and Appendices 1 – 15. 
 
Table 2. Thyroid Function and Serological Data of All Study Subjects from HSM-
CHULN, followed from 2009 ± 6 to 2014 ± 3 
 First Visit Last Visit 
 n Mean ± σ Median n Mean ± σ Median 
TSH 333 7.7 ± 29.3 2.9 244 3.9 ± 9.2 2.2 
T3 327 131 ± 45 126 242 109 ± 32 104 
T4 328 8.7 ± 2.5 8.6 239 8.6 ± 2.4 8.4 
fT4 314 1.3 ± 3.3 1.1 239 1.3 ± 0.6 1.2 
Tg 150 93 ± 442 18 158 50 ± 240 11 
TPOAb 326 966 ± 4254 151 234 527 ± 1957 85 
TgAb 325 781 ± 4088 38 230 504 ± 2412 38 
 
TPOAb and TgAb Characteristics 
The prevalence of TPOAb positivity was 66,8% (n = 231) at the first visit, and 
41,3% (n = 143) at the last visit. The prevalence of TgAb positivity was 46% (n = 159) 
at the first visit, and 31,8% (n = 110) at the last visit. 
The difference between TPOAb positivity at the first and last visits was 
statistically significant (p < 0.001). The difference between TgAb positivity at the first 
and last visits was statistically significant (p = 0.001). The difference between TPOAb 
positivity and TgAb positivity at the first visit was statistically significant (p < 0.001). 
The difference between TPOAb positivity and TgAb positivity at the last visit was 
statistically significant (p < 0.001). 
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Serum concentrations of TPOAb were higher than serum concentrations of 
TgAb in both visits, but this difference was only statistically significant at the first visit 
(z = -5,842, n = 324, p < 0.001). 
 At the first visit, 55.7% (n = 193) of patients presented with higher serum TPOAb 
concentrations than serum TgAb concentrations, 28.6% (n = 99) of patients presented 
with higher serum TgAb concentrations than serum TPOAb concentrations and only 
8.1% (n = 28) of patients presented with equal concentrations of both antibodies (n 
missing = 22). For patients who had higher serum TPOAb concentrations, the mean 
time of disease was 9 ± 7 years. For patients who had higher serum TgAb 
concentrations, the mean time of disease was 6 ± 6 years. 76 patients presented with 
serum TPOAb concentrations 10 times higher than serum TgAb concentrations, while 
only 27 patients presented with serum TgAb concentrations 10 times higher than serum 
TPOAb concentrations. 
 At the last visit, 30.1% (n = 104) of patients presented with higher serum TPOAb 
concentrations than serum TgAb concentrations, 28.9% (n = 100) of patients presented 
with higher serum TgAb concentrations than serum TPOAb concentrations and only 
5.9% (n = 20) of patients presented with equal concentrations of both antibodies (n 
missing = 119). For patients who had higher serum TPOAb concentrations, the mean 
time of disease was 9 ± 7. For patients who had higher serum TgAb concentrations, the 
mean time of disease was 10 ± 8. 42 patients presented with serum TPOAb 
concentrations 10 times higher than serum TgAb concentrations, while only 22 patients 
presented with serum TgAb concentrations 10 times higher than serum TPOAb 
concentrations. 
 
Differences in Thyroid Antibodies and Function Between Visits 
Serum concentrations of TSH, T3, T4 and TPOAb were significantly reduced 
between the first and last visits (z = -2.748, n = 242, p = 0.006; z = -8.859, n = 237, p < 
0.001; z = -2.091; n = 235, p = 0.037; z = -5.706, n = 230, p < 0.001; respectively), as 
shown in Appendix 16 and illustrated in Figure 1a, 1b, 1c, 1f. 
However, serum fT4 was significantly increased between the first and last visits, 
(z = - 3.362, n = 221, p = 0.01), as shown in Appendix 16 and illustrated in Figure 1d. 
There were no statistically significant differences between visits for serum 
concentrations of Tg and TgAb, even though we observed a reduction in their titers 
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Figure 1. Serum levels between first 
(left) and last (right) visits of (a) TSH 
(14 outliers removed of maximum value 
= 446000), (b) T3, (c) T4, (d) fT4 (2 
outliers removed of maximum value = 
59), (e) Tg (3 outliers removed of 
maximum value 4500), (f) TPOAb (3 
outliers removed of maximum value 
46000), (g) TgAb (16 outliers removed 
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Influence of Thyroid Antibodies on Other Thyroid Parameters in the Absence of 
Therapy 
1. First Visit 
 At the first visit of non-treated patients, there was a significant yet weak positive 
correlation between the serum TPOAb levels and serum TgAb levels (r = 0.275, n = 
170, p < 0.001), as shown in Appendix 17. Increases in serum TPOAb levels correlated 
with increases in serum TgAb levels. 
There was a significant weak positive correlation between the serum TPOAb 
levels and serum TSH levels (r = 0.212, n = 169, p = 0.006), as shown in Appendix 17. 
Increases in serum TPOAb levels correlated with increases in serum TSH levels. 
There was a significant weak negative correlation between the serum TPOAb 
levels and serum fT4 levels (r = -0.194, n = 158, p = 0.014), as shown in Appendix 17.  
Increases in serum TPOAb levels correlated with decreases in serum fT4 levels. 
Serum TPOAb levels did not significantly correlate with serum T3, T4 or Tg, as 
shown in Appendix 17. 
There was a significant weak negative correlation between the serum TgAb 
levels and serum Tg levels (r = -0.319, n = 80, p = 0.004), as shown in Appendix 18. 
Increases in serum TgAb levels correlated with decreases in serum Tg levels. 
Serum TgAb levels did not significantly correlate with serum TSH, T3, T4 or 
fT4, as shown in Appendix 18. 
 
2. Last Visit 
At the last visit, serum TPOAb levels did not significantly correlate with serum 
TgAb, TSH, T3, T4, fT4 or Tg, as shown in Appendix 19. 
 There was a significant weak negative correlation between the serum TgAb 
levels and serum Tg levels (r = -0.370, n = 46, p = 0.011), as shown in Appendix 20. 
Increases in serum TgAb levels correlated with decreases in serum Tg levels. 
Serum TgAb levels did not significantly correlate with serum TSH, T3, T4 or 






Study Population Subset with Positive Tg and Positive TgAb 
 At the first visit, there were 13 patients who presented with positive Tg and 
positive TgAb. They were all women. Their descriptive data is shown on Table 3.  
 At the last visit, there were 10 patients who presented with positive Tg and 
positive TgAb. They were all women. Their descriptive data is shown on Table 4. 
 
 
Table 3. Demographic, biochemical and serological data of patients with positive Tg 
and positive TgAb, at the first visit 
 n Mean ± σ 
Age 13 51 ± 16 
Time since diagnosis 3 11 ± 12 
TSH1 13 14,5 ± 40,8 
T31 13 121,9 ± 60,8 
T41 13 7,6 ± 3,2 
FT41 12 1 ± 0,2 
Tg1 13 102,8 ± 49,4 
TPOAb1 12 992 ± 2842,5 
TgAb1 13 955,8 ± 2720,5 
TSHL 5 2,2 ± 1,3 
T3L 5 113,8 ± 17 
T4L 5 9,7 ± 1,97 
FT4L 4 1,1 ± 0,1 
TgL 5 74,8 ± 49,2 
TPOAbL 5 106,6 ± 123,4 









Table 4. Demographic, biochemical and serological data of patients with positive Tg 
and positive TgAb, at the last visit 
 n Mean ± σ 
Age 8 56 ± 21 
Time since diagnosis 2 7,5 ± 4,9 
TSH1 10 3,5 ± 2,63 
T31 10 130,5 ± 54,7 
T41 10 8,4 ± 2,3 
FT41 10 1 ± 0,2 
Tg1 5 197,8 ± 142,95 
TPOAb1 10 802,6 ± 902,4 
TgAb1 10 244,4 ± 554,249 
TSHL 10 3,4 ± 2,6 
T3L 10 105,6 ± 27,1 
T4L 9 8,1 ± 2,99 
FT4L 10 1,2 ± 0,3 
TgL 10 138,6 ± 51,7 
TPOAbL 10 1714,2 ± 3210,6 
















Although autoimmune thyroid disease is a prevailing autoimmune disorder and 
the most common cause of primary hypothyroidism in iodine sufficient populations, the 
functional and clinical role of antithyroid antibodies has not been fully elucidated [1], 
[107]. 
While TPOAb is thought to be the most accurate serological biomarker for 
thyroid autoimmunity, with demonstrated pathogenic consequences, TgAb is less useful 
and its role is uncertain in autoimmune thyroid disease [25]. 
The determination of possible relations between TPOAb and TgAb with thyroid 
hormones and their temporal evolution would be helpful in enlightening their pathologic 
role autoimmune thyroid disease. 
 
Study Population Profile 
In the present study, patients were mainly female and middle-aged, which is in 
agreement with demographic distribution usually described for autoimmune thyroid 
disease [1]. Older age and female sex are crucial risk factors for the development of 
Hashimoto’s thyroiditis [11]. In addition, the frequency of TPOAb and TgAb positivity 
increases with age in women [25], [27]. The female preponderance is likely due to sex 
steroid effects on the immune response, but a skewed X chromosome inactivation and 
fetal microchimerism have been proposed as alternative explanations [11]. 
Long standing disease in Hashimoto’s thyroiditis, as was the case for our study 
population, is also a common finding as the initial course of disease is most often silent, 
and formal diagnosis takes place years after disease onset [108]. 73% of patients in our 
study population had thyroid dysfunction at presentation, but most were already under 
levothyroxine therapy. Nevertheless, an euthyroid presentation and subclinical 
hypothyroidism in Hashimoto’s thyroiditis are not uncommon [10], [22], demonstrating 
the indolent nature of the underlying autoimmune process and the scope of the 
compensatory action of TSH [109]. 
 
Relationship between TPOAb and TgAb 
Autoantibody prevalence in Hashimoto’s thyroiditis has been reported as nearly 
100% for TPOAb and 60–80% for TgAb [5, 6]. In our study, all patients were positive 
for one or the other antibody, as antibody positivity was one of the selection criteria for 
the study population. Furthermore, TPOAb was more frequently measurable than TgAb 
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(66,8% versus 46% at the first visit; 41,3% versus 31,8% at the last visit; respectively), 
with a statistically significant difference, which is consistent with antithyroid antibody 
status described in previous studies [30], [37], [110]–[114]. 
In comparison to TgAb, TPOAb displays higher serum concentrations in 
autoimmune thyroid disease [9]. Overall, serum concentrations of TPOAb were higher 
than TgAb, in our study sample, but this difference was only statistically different for 
the first visit. However, if one considers only the qualitative value of the antibodies 
(positive versus negative), the proportion of TPOAb positivity was significantly higher 
than the proportion of TgAb positivity in both visits. Additionally, the wide range in 
quantitative values of TPOAb and TgAb we found was also documented in different 
studies [111], [115], [116]. 
Nonetheless, almost one third of patients in both visits had higher serum TgAb 
concentrations than TPOAb. Thus, there were patients who preferentially produced 
TPOAb, while others mainly developed TgAb. Carlé et al. found no differences in 
patient characteristics (sex, age, iodine status and goiter) between these two patient 
groups, in their study population, and proposed that a random phenomenon might 
determine which antibody is predominantly generated [111]. 
We reported a significant positive but only modest correlation between the two 
antibodies (TPOAb and TgAb) in our study population of Hashimoto’s thyroiditis 
patients, a similar finding to other population-based studies. However, this correlation 
was only found at the first visit. Carlé et al. analyzed autoantibody status in 186 patients 
with primary hypothyroidism and observed a significant positive weak correlation 
between log TPOAb and log TgAb (r2 = 0.11, p < 0.001, n = 145) [111]. Likewise, a 
review by Caturegli et al. analyzed 6200 serum samples from the 2007–2008 NHANES 
survey and 4977 serum samples tested by the Johns Hopkins Immunology Laboratory 
and noted, again, a significant positive weak correlation between TPOAb and TgAb in 
both groups (r2 = 0.21; r2 = 0.46; p < 0.0001; respectively) [22]. Feldt-Rasmussen et al. 
defined a significant positive weak correlation between the quantitative concentrations 
of TPOAb and TgAb (Spearmann's rho = 0.65, p < 0.001), for both thyroid diseases and 
non-thyroid autoimmune diseases. 
It is worth questioning if the weak nature of the correlation between TPOAb and 




Caturegli et al. have argued that the weak correlation between the two 
autoantibodies suggests they are expressed at different stages of disease, with TgAb 
preceding the appearance of TPOAb [22]. An immune escalation mechanism has been 
proposed, where TgAb would be present at disease onset as an initial response from the 
innate immune system and TPOAb would represent an ensuing adaptive immune 
response [22], [117]. In fact, this was demonstrated in mouse models of spontaneous 
autoimmune thyroiditis [118]. In human subjects, diagnosis of Hashimoto’s thyroiditis 
usually takes places years after disease onset, hence TPOAb are expected to be more 
prevalent and at higher serum titers [22]. 
Could this mechanism simultaneously explain the weak antibody correlation and 
the reason why certain patients mainly developed TgAb instead of TPOAb? Following 
the immune escalation model, patients who mainly expressed TgAb would be at earlier 
stages of disease. Interestingly, Carlé et. al also found that serum TSH tended to be 
lower in patients predominantly positive for TgAb, even though this was not statistically 
significant [111]. Serum TSH is expected to increase as thyroid hormone production 
decreases, which would be the outcome of progressive autoimmune thyroiditis [109]. 
By this line of thinking, higher TSH levels, like higher TPOAb levels, would be 
expected at later stages of disease. 
One question remains to be answered: why was the correlation between TPOAb 
and TgAb not found at the last visit? If the last visit represents a later stage of disease, 
according to the immune escalation hypothesis, the discrepancy between TPOAb and 
TgAb production and corresponding serum levels would be even more skewed towards 
TPOAb at this stage. Thus, a correlation would be less likely at later stages of disease. 
27 and 22 patients had serum TgAb concentrations 10 times higher than serum 
TPOAb concentrations at the first and last visits, respectively. It is questionable if such 
a considerable disparity fits the immune escalation model or if this subset of patients 
represents a different clinical situation, such as a specific immune response triggered by 
differentiated thyroid cancer [48], [58]–[61], [119]. In fact, TgAb has been shown to 
respond to changes in the mass of Tg-secreting thyroid tissue [80]. Simultaneously, the 







Differences in Thyroid Antibodies and Function Between Visits 
In the present study, TSH, T3, T4 and TPOAb titers were reduced and fT4 titers 
were increased between visits. TgAb and Tg levels were decreased between visits, but 
such difference was not statistically significant. Despite this, the number of TgAb 
positive cases was significantly reduced between visits. The same applied to the number 
of TPOAb positive cases. We equate two possible reasons to explain these findings. 
First, one cannot overlook the possible influence of levothyroxine, as the 
percentage of patients under levothyroxine therapy in our study increased from 49% to 
73% between visits. A recent systematic review and meta-analysis reviewing 25 
randomized clinical trials concerning the clinical efficacy of levothyroxine in the 
treatment of overt and subclinical hypothyroidism reported, when comparing the 
levothyroxine group and the placebo group: a significant decrease in TSH and increase 
in fT4 in both overt or subclinical hypothyroidism; and no significant difference in T3 
for overt hypothyroidism, but a significant decrease in T3 for subclinical 
hypothyroidism [121]. Thyroid hormone replacement achieves normal TSH titers, by 
correcting the overstimulation of the hypothalamic-pituitary-thyroid axis [109], [122]. 
Reduced TSH levels could contribute to reduced T3, T4 and Tg levels, by the decrease 
of stimulation of the thyroid gland. Previous research reports decrease of TPOAb levels 
following levothyroxine therapy [112], [123]–[127]. Chiovato et al. argued that such a 
decrease in TPOAb titers could not be due to spontaneous fluctuations of antibody, as 
they did not find a similar significant decrease in euthyroid patients with Hashimoto's 
thyroiditis [112]. TPO gene expression and activity as well as targeting of TPO to the 
thyrocyte membrane is a TSH enhanced phenomenon [24], [128]–[130]. As argued by 
other authors, the suppression of serum TSH levels by levothyroxine therapy could 
cause a reduction in expression of the TPO autoantigen, halting the ensuing 
autoimmune response and decreasing TPOAb levels [112], [126], [127]. In fact, Guclu 
et al. also showed a reduction in inflammatory markers (serum IL-12 and IFN-γ) 
involved in the pathogenesis of Hashimoto’s thyroiditis, and we hypothesize it could 
mirror an overall decrease in the autoimmune response [126]. The reduced stimulation 
of the thyroid gland by TSH could also account for a decrease of TgAb. This protein has 
been shown to be dependent on TSH [45], [49]. 
Second, we must consider the natural history of Hashimoto’s thyroiditis. The 
destructive process in chronic lymphocytic thyroiditis entails atrophy of the follicular 
epithelium paired with variable degrees of fibrosis of the thyroid gland [131]. Follicular 
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atrophy and colloid loss could lead to the gradual loss of thyroid hormonogenesis, 
accounting for the reduction in T3, T4 and Tg. In a similar fashion to what was 
demonstrated in thyroid cancer, the reduction of thyroid antibodies could be explained 
by the atrophy and fibrosis of the thyroid gland. In differentiated thyroid cancer, 
complete removal of thyroid tissue by total thyroidectomy and radioablation therapy, 
with its antigenic elements and intrathyroidal lymphocytes, is expected to yield full 
disappearance of all major anti-thyroid antibodies in the serum, with a median 
disappearance time of 3 years for TgAb and of 6.3 years for TPOAb [80]. Chiovato et 
al. reported a statistically significant correlation between the disappearance of thyroid 
tissue and that of anti-thyroid antibodies [80]. In this scenario, the elimination of 
inciting thyroid antigens removes the stimulus that drives antibody production and 
antigen presentation to the immune system, whilst the elimination of intrathyroidal 
lymphocytes equates the eradication of the main source of anti-thyroid antibody 
production. We hypothesize that the atrophy of the thyroid gland could result in the 
partial depletion of thyroid autoantigens and intrathyroidal B cells, thereby partially 
removing the stimulus and main sources for production of antithyroid antibodies. To the 
best of our knowledge no studies correlate the degree of thyroid atrophy with expression 
of thyroid autoantigens and respective antibodies. 
 
Influence of Thyroid Antibodies on Other Thyroid Parameters 
 A significant yet weak positive correlation between the serum TPOAb levels and 
serum TSH levels was found at the first visit, but not at the last visit. This correlation 
between TSH levels and TPOAb titers was found in hypothyroid patients and in 
euthyroid individuals in other studies [28], [113], [115], [132]–[134]. The relationship 
between TPO and TSH highlighted above could also explain such an association. 
Conversely, Roos et al. suggested that this correlation, and the fact that TSH and 
TPOAb were independent predictors of future development of hypothyroidism, could 
mean that the maintenance of euthyroidism in the presence of TPOAb required a 
compensatory increase in TSH levels [28].  
TPOAb titers negatively, but weakly, correlated with fT4 levels only at the first 
visit. TPOAb have pathogenic potential in Hashimoto’s thyroiditis – they fix 
complement, promote cell-mediated cytotoxicity and C3 complement-mediated 
cytotoxicity, and competitively inhibit TPO’s enzymatic activity [20], [26], [31]–[34] –, 
but its translation in vivo and the importance it takes in the overall autoimmune process 
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is dubious. TPOAb were found to correlate with thyroid dysfunction [25]. The negative 
correlation between TPOAb and fT4 can clarify the positive correlation between 
TPOAb and TSH. If TPOAb decrease fT4, it would result in a compensatory increase of 
TSH. 
TPOAb were not found to correlate with T3 or T4. A study encompassing 311 
participants (261 diagnosed with autoimmune thyroid diseases) found a significant 
correlation between serum T3 and TPOAb as well as TgAb [115]. Another study of 
2425 subjects under suspicion of thyroid disease showed a correlation between serum 
T4 and TPOAb [134]. This inconsistent relationship of TPOAb with T3 and T4 could be 
caused by the binding of these hormones to thyroxine-binding globulin and other 
transport plasma proteins. 
We found no correlation between TgAb and TSH, even though abnormal TSH 
levels were associated with abnormal Tg levels and increased production of TgAb [45], 
[49], [113]. 
TgAb titers did not correlate with T3, T4 or fT4. TgAb are not complement 
fixing and do not cause thyroid cell destruction [42], hence it could have an even 
smaller probability of influencing thyroid hormone levels. 
Predictably, there was a significant negative but weak between serum TgAb and 
Tg levels, at both visits. Because TgAb are directed against Tg, this correlation is 
expected. TgAb interference nullifies serum Tg measurements, once it can lead to false 
results in any Tg assay [68], [69]. Theoretically, the presence of TgAb leads to the 
negativization of Tg measurements, which could explain the weak correlation. 
Moreover, the TgAb interference does not seem to be completely concentration 
dependent, as low concentrations of TgAb might interfere with Tg measurements and 
high concentrations of TgAb might not [54], [70], [135], further explaining the 
significant but weak correlation. In a practical scenario, this means it is difficult to 
predict the degree of Tg under estimation or over estimation based on the TgAb 
concentration [120]. 
 
Study Population Subset with Positive Tg and Positive TgAb 
A small number of patients presented with positive Tg and TgAb. The expected 
TgAb interference in Tg quantitation methods results in spuriously low Tg results, 
which makes this population subset unexpected. A few hypotheses could substantiate 
this clinical scenario. First, TgAb interference can cause falsely high Tg results, 
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especially in radioimmunoassays (RIA) [72], [73]. In addition, as stated above, the 
TgAb concentration does not show a linear correlation with TgAb interference [54], 
[70], [135]. Second, the presence of heterophile antibody (HAb), whose screening is not 
routinely done, may result in falsely high serum Tg immunometric assays (IMA) 
measurements [71]. Third, if these subsets represent patients with differentiated thyroid 
cancer, the true value of Tg can be very elevated, largely surpassing the capacity of 
TgAb interference. Again, it has been shown that the majority of differentiated thyroid 
cancer show an increased preoperative serum Tg [120]. Fourth, the heterogeneity of 
both Tg and TgAb offer an additional explanation [48], [58]–[61]. In the setting of 
thyroid cancer, TgAb could be directed against normal Tg, as part of the Hashimoto’s 
thyroiditis response, and the assays could be measuring tumoral Tg. The opposite also 
applies: TgAb could be directed against a tumoral Tg with increased immunogenicity, 




This study has potential limitations, which weaken our findings. First, this is a 
retrospective and single center study with a relatively small sample of patients. 
Therefore, our study population characteristics might not match those of the general 
Hashimoto’s thyroiditis population. In addition, our study’s database was based in 
patient’s clinical records, and both might be subject to a registry bias. Considering the 
indolent nature of Hashimoto’s thyroiditis, the follow-up period might not have been 
enough to reflect the magnitude of change in thyroid function and antibodies. Another 
limitation would be that therapeutic adherence to levothyroxine was not evaluated. 
Unfortunately, we did not have the support of the Clinical Pathology Department to 
further investigate a few of our hypothesis to explain our findings. 
 
Conclusion 
Our knowledge on Hashimoto’s thyroiditis remains ever expanding. The 
clarification of relationship and temporal evolution of antithyroid antibodies and thyroid 
function could help elucidate Hashimoto’s thyroiditis pathogenesis and, eventually, help 
define the management of these patients. The follow-up change we observed in 
antithyroid antibodies and thyroid function shows us that Hashimoto’s thyroiditis is not 
an immutable disease. The correlation between TPOAb and fT4 and TSH might suggest 
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this antibody’s importance has been disregarded. The difference in TPOAb and TgAb 
expression in distinct patient subsets could reflect the evolution of Hashimoto’s 
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Appendix 1. Age distribution of all study subjects from HSM-CHULN, followed 





































Appendix 2. Log transformed serum TSH distribution from the first visit of all study 
subjects from HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
Appendix 3. Log transformed serum TSH distribution from the last visit of all study 





































Appendix 4. Serum T3 distribution, from the first visit, of all study subjects from 
HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
Appendix 5. Serum T3 distribution, from the last visit, of all study subjects from 





































Appendix 6. Serum T4 distribution, from the first visit, of all study subjects from 
HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
Appendix 7. Serum T4 distribution, from the last visit, of all study subjects from 





































Appendix 8. Log transformed serum fT4 distribution, from the first visit, of all study 
subjects from HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
Appendix 9. Log transformed serum fT4 distribution, from the last visit, of all study 























Appendix 10. Log transformed serum Tg distribution, from the first visit, of all 
study subjects from HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
Appendix 11. Log transformed serum Tg distribution, from the last visit, of all study 





































Appendix 12. Log transformed serum TPOAb distribution, from the first visit, of all 
study subjects from HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
Appendix 13. Log transformed serum TPOAb distribution, from the last visit, of all 





































Appendix 14. Log transformed serum TgAb distribution, from the first visit, of all 
study subjects from HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
Appendix 15. Log transformed serum TgAb distribution, from the last visit, of all 
study subjects from HSM-CHULN, followed from 2009 ± 6 to 2014 ± 3. 
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Appendix 16. Results of the Wilcoxon Signed-Rank Test to detect differences 
between first and last visits in all variables 
Variables z p-value n n detailed 
TSH -2.748 0.006 242 Negative: 137 
Positive: 103 
Ties: 2 
T3 -8.859 <0.001 237 Negative: 184 
Positive: 53 
Ties: 0 
T4 -2.091 0.037 235 Negative: 135 
Positive: 96 
Ties: 4 
fT4 -3.362 0.01 221 Negative: 88 
Positive: 124 
Ties: 9 
Tg -0.744 NS (0.457) 71 Negative: 36 
Positive: 33 
Ties: 2 
TPOAb -5.706 <0.001 230 Negative: 155 
Positive: 59 
Ties: 16 















Appendix 17. Results of the Spearman Rank Order Regression to detect relations 
between TPOAb and TgAb, TSH, T3, T4, fT4 and Tg at the first visit of non-treated 
patients 
Variables r n p-value 
TgAb1 0.265 170 < 0.001 
TSH1 0.212 169 0.006 
T31 -0.010 167 NS (0.897) 
T41 -0.003 169 NS (0.973) 
fT41 -0.194 158 0.014 
Tg1 -0.060 80 NS (0.595) 
 
 
Appendix 18. Results of the Spearman Rank Order Regression to detect relations 
between TgAb and TPOAb, TSH, T3, T4, fT4 and Tg at the first visit of non-treated 
patients 
Variables r n p-value 
TSH1 -0.012 169 NS (0.881) 
T31 -0.327 167 NS (0.327) 
T41 -0.038 169 NS (0.627) 
fT41 -0.098 158 NS (0.221) 
Tg1 -0,319 80 0.004 
 
 
Appendix 19. Results of the Spearman Rank Order Regression to detect relations 
between TPOAb and TgAb, TSH, T3, T4, fT4 and Tg at the last visit of non-treated 
patients 
Variables r n p-value 
TgAbL 0.188 67 NS (0.127) 
TSHL 0.139 70 NS (0.251) 
T3L 0.060 68 NS (0.625) 
T4L -0.119 67 NS (0.339) 
fT4L -0.112 71 NS (0.354) 




Appendix 20. Results of the Spearman Rank Order Regression to detect relations 
between TgAb and TPOAb, TSH, T3, T4, fT4 and Tg at the last visit of non-treated 
patients 
Variables r n p-value 
TSHL -0.026 67 NS (0.832) 
T3L 0.069 66 NS (0.582) 
T4L 0.060 65 NS (0.635) 
fT4L 0.113 68 NS (0.359) 























RESUMO ALARGADO EM PORTUGÊS 
Introdução 
 As doenças autoimunes da tiróide, incluindo a tiroidite de Hashimoto e doença de 
Graves, permanecem as doenças autoimunes mais frequentes na população adulta. 
Existe uma preponderância do sexo feminino em todos os tipos de doenças autoimunes 
da tiróide, exceto na tiroidite relacionada com IgG4. 
 Tanto a tiroidite de Hashimoto quanto a doença de Graves exibem uma infiltração 
da glândula tiroideia e a presença de anticorpos contra autoantigénios tiroideus, mais 
frequentemente contra a peroxidase tiroideia, tiroglobulina e recetor da hormona 
estimuladora da tiróide. 
 Com a exceção dos anticorpos contra o recetor da TSH, os autoanticorpos 
tiroideus, embora úteis para o diagnóstico de doença autoimune da tiróide, assumem-se 
desprovidos de relevância fisiológica ou clínica e poderão ser determinados apenas uma 
vez, na primeira consulta. 
 André Gide, escritor francês, disse que chamamos experiência à repetição dos 
mesmos erros. Como tal, decidimos desafiar as suposições tradicionais ao explorar 
dados dos nossos doentes com tiroidite de Hashimoto. 
 Começaremos por resumir a relevância e utilidade clínicas atuais dos anticorpos 
antitiroideus neste Trabalho Final de Mestrado. Como estudo retrospetivo 
observacional, iremos examinar a inter-relação dos anticorpos antitiroideus e a 
influência dos anticorpos antitiroideus sobre outros parâmetros da função tiroideia bem 
como a evolução dos anticorpos antitiroideus e função tiroideia ao longo do tempo, na 
tiroidite de Hashimoto. 
 Os anticorpos anti-peroxidase são imunoglobulinas policlonais firigidas contra a 
peroxidase tiroideia, uma enzima tiroideia chave, localizada na membrana apical dos 
tirócitos e responsável por catalisar a oxidação do iodo, organificação da Tg e 
emparelhamento intra-cadeia dos resíduos de tirosina iodinados, de forma a gerar T4 e 
T3. 
 Os TPOAb são encontrados em 5-20% da população geral. Os TPOAb 
encontrados nos indivíduos sem disfunção tiroideia parecem diferir dos TPOAb 
encontrados na doença autoimune da tiróide, na medida em que não bloqueiam a 
atividade da TPO ou interferem com as ações dos TPOAb associados à doença 
autoimune da tiróide. O seu significado é incerto nesta população sem doença tiroideia. 
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 A deteção de TPOAb ocorre em 90-95% dos doentes com doença autoimune da 
tiróide, quase 100% dos doentes com tiroidite de Hashimoto e 80% dos doentes com 
doença de Graves. Estes TPOAb associados à doença autoimune da tiróide fixam 
complemento, promovem a citotoxicidade celular e citotoxicidade mediada por C3, 
contribuindo para danificar os tirócitos, bem como inibem competitivamente a ativiade 
enzimática da TPO. 
 Os TPOAb constituem o marcador serológico mais sensível para a presença de 
autoimunidade tiroideia, especialmente em comparação com TgAb. Apenas a presença 
de TPOAb positivos se correlacionou com a presença de disfunção tiroideia. 
Adicionalmente, verifica-se uma correlação significativa entre o grau de tiroidite 
linfocítica e os níveis de TPOAB. 
 A medição de TPOAb participa na investigação do hipotiroidismo, contribuindo 
para definir a respetiva etiologia como tiroidite de Hashimoto. Por outro lado, a sua 
determinação também se encontra recomendada para a avaliação do hipotiroidismo 
subclínico, já que níveis elevados de TPOAb predizem a progressão para hipotiroidismo 
manifesto (taxa anual de progressão de 4.3% se TPOAb positivo versus 2.6% para 
TPOAb negativo). Nos doentes com hipotiroidismo subclínico, níveis elevados de 
TPOAb poderão justificar uma monitorização cautelosa ou influenciar a decisão sobre o 
início do tratamento. A repetição da medição dos TPOAb não está recomendada em 
guidelines internacionais, quer no hipotiroidismo manifesto quer no hipotiroidismo 
subclínico. 
Os anticorpos anti-tiroglobulina são imunoglobulinas policlonais dirigidas contra 
a tiroglobulina, uma glicoproteína armazenada no colóide tiroideu, responsável por 
fornecer o molde para a síntese de hormonas tiroideias, armazenamento de iodo e 
modulação da função folicular tiroideia. 
Apesar de reconhecidos como parte integrante dos mecanismos de autoimunidade 
tiroideia, os TgAb encontram-se presentes em 10% da população geral sem evidência de 
doença tiroideia. 
A deteção de TgAb ocorre em ocorre em 60% dos doentes com doença autoimune 
da tiróide, quase 60-80% dos doentes com tiroidite de Hashimoto e 50-60% dos doentes 
com doença de Graves. Como tal, é um marcador menos sensível que os TPOAb para a 
autoimunidade tiroideia. Na ausência de TPOAb, os TgAb não se associam a disfunção 
tiroideia. Na doença autoimune da tiróide, o seu papel funcional é incerto, uma vez que 
não fixam complemento nem causam destruição das células tiroideias. 
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A medição dos TgAb não é necessária para o diagnóstico de doença autoimune da 
tiróide e não incorpora a abordagem do hipotiroidismo. 
Os TgAb cumprem o seu principal papel na neoplasia diferenciada da tiróide, 
onde registam uma prevalência de 25-30% (uma taxa duas vezes superior à população 
geral). 
No contexto pós-tratamento, a determinação dos TgAb pretende garantir a 
fiabilidade da Tg como marcador de doença neoplásica persistente ou recorrente, após 
eliminação completa de tecido tiroideu através de tiroidectomia total e terapêutica 
radioablativa. Isto porque a presença de TgAb inviabiliza as medições de Tg por 
mecanismos de interferência, em qualquer dos métodos de quantificação utilizados. A 
constatação de que as concentrações de TgAb respondem a alterações na massa de 
tecido tiroideu secretor de Tg resultou na evolução do papel dos TgAb na neoplasia 
diferenciada da tiróide. A tendência dos níveis de TgAb provou ser um marcador de 
substituição robusto da Tg para detetar doença persistente ou recorrente. Uma tendência 
descendente de TgAb indica baixo risco de persistência ou recorrência de doença. Uma 
tendência ascendente ou aparecimento de novo de TgAb é sugestivo de doença 
persistente ou recorrente. 
No contexto pré-operatório, níveis elevados de TgAb predizem fracamente o 
diagnóstico de cancro da tiróide em nódulos tiroideus, mas a sua medição para tais 
efeitos diagnósticos não é recomendada em normas de orientação clínica internacionais. 
 
Doentes e Métodos 
1. Doentes 
No presente estudo retrospetivo observacional, examinámos uma base de dados 
abrangendo 346 doentes diagnosticados com tiroidite de Hashimoto, seguidos na 
consulta externa de Endocrinologia de um hospital público central em Lisboa (Hospital 
de Santa Maria — Centro Hospitalar Universitário Lisboa Norte; HSM-CHULN), de 
2009 ± 6 até 2014 ± 3. Todos os doentes assinaram um consentimento informado para 
autorização da utilização dos seus dados clínicos em investigações futuras, após 
aprovação pela Comissão de Ética do referido hospital. 
O diagnóstico de tiroidite de Hashimoto foi definido como TPOAb ou TgAb 
positivos e ausência de hipertiroidismo.  
As seguintes variáveis, recolhidas anonimamente e incluídas na base de dados, 
foram analisadas: (1) sexo; (2) idade (em anos); (3) diagnóstico; (4) tempo decorrido 
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desde diagnóstico (em anos); (5) tempo de seguimento (em anos); (6) TSH, T3, T4, fT4, 
Tg, TPOAb, TgAb e rácio TPOAb/TgAb nas primeira e última consultas; (7) presença 
de disfunção tiroideia na primeira consulta (definida por TSH fora do intervalo de 
referência normal); (8) terapêutica com levotiroxina na primeira e última consultas. 
As amostras sanguíneas dos doentes foram colhidas no período da manhã (8 – 
10h) no Departamento de Patologia Clínica, após um jejum noturno. Todas as variáveis 
relacionadas com a função tiroideia e anticorpos antitiroideus foram avaliadas por 
métodos padrão de imunoquimioluminescência, utilizando ensaios comerciais 
disponíveis no Departamento de Patologia Clínica do HSM-CHULN. Este 
departamento está em conformidade com os padrões de prática clínica e é uma 
instalação registada e certificada. Os intervalos de referência normais considerados 
encontram-se apresentados na Tabela 1. 
2. Análise Estatística 
A análise estatística dos dados foi realizada utilizando o programa de software 
estatístico IBM SPSS versão 26.0 (IBM Corp. Released 2019. IBM SPSS Statistics for 
Windows, Version 26.0. Armonk, NY: IBM Corp.). O limite de significância estatística 
foi estabelecido para valor-p bicaudal < 0.05. 
A normalidade dos dados foi verificada com o teste Kolmogorov-Smirnov. 
Foram utilizados testes não paramétricos para as variáveis com distribuição não normal. 
As diferenças entre variáveis emparelhadas das primeira e última consultas foram 
detetadas com o teste não paramétrico Wilcoxon Signed-Rank. O teste Qui-Quadrado 
(χ2) foi realizado para testar as diferenças no número positividade de TPOAb e TgAb 
em ambas visitas e entre visitas. O teste não paramétrico Spearman Rank Order 
Regression foi realizado para determinar a relação entre os anticorpos antitiroideus 
(TPOAb e TgAb) e os testes de função tiroideia bem como outras variáveis clínicas. 




1. Perfil da População em Estudo 
Os dados demográficos de 346 doentes foram analisados, 90% dos quais eram 
do sexo feminino (n = 310). A maioria dos doentes era de meia idade (51 ± 17 anos na 
primeira consulta), com doença de longa duração (8 ± 8 anos). Apenas 24% dos doentes 
apresentavam-se com disfunção tiroideia e 49% estavam sob tratamento com 
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levotiroxina (pelo que, um total de 73% de doentes apresentava disfunção tiroideia), na 
primeira consulta. Na última consulta, após um tempo de seguimento médio de 5 ± 4 
anos, 9% dos doentes apresentavam-se com disfunção tiroideia e 73% dos doentes 
encontravam-se medicados com levotiroxina (pelo que, um total de 82% de doentes 
apresentava disfunção tiroideia). 
Os dados bioquímicos e serológicos de todos os doentes estão representados no 
Tabela 2 e Anexos 1 – 15. 
2. Características de TPOAb e TgAb 
A prevalência de TPOAb positivo foi 66,8% (n = 231) na primeira consulta, e 
41,3% (n = 143) na última consulta. A prevalência de TgAb positivo foi 46% (n = 159) 
na primeira consulta, e 31,8% (n = 110) na última consulta. 
A diferença entre a positividade de TPOAb entre a primeira e última consultas 
foi estatisticamente significativa (p < 0.001). A diferença entre a positividade de TgAb 
entre a primeira e última consultas foi estatisticamente significativa (p = 0.001). A 
diferença entre a positividade de TPOAb e a positividade de TgAb na primeira consulta 
foi estatisticamente significativa (p < 0.001). A diferença entre a positividade de 
TPOAb e a positividade de TgAb na última consulta foi estatisticamente significativa (p 
< 0.001). 
As concentrações séricas de TPOAb foram superiores às concentrações séricas 
de TgAb em ambas consultas, mas esta diferença foi estatisticamente significativa 
apenas na primeira consulta (z = -5,842, n = 324, p < 0.001). 
Na primeira consulta, 55.7% (n = 193) dos doentes apresentavam concentrações 
séricas de TPOAb superiores às concentrações séricas de TgAb, 28.6% (n = 99) dos 
doentes apresentavam concentrações séricas de TgAb superiores às concentrações 
séricas de TPOAb e apenas 8.1% (n = 28) apresentavam concentrações iguais de ambos 
anticorpos (n em falta = 22). Para os doentes com concentrações séricas de TPOAb 
superiores, o tempo médio de doença foi 9 ± 7 anos. Para os doentes com concentrações 
séricas de TgAb superiores, o tempo médio de doença foi 6 ± 6 anos. 76 doentes 
apresentavam concentrações séricas de TPOAb 10 vezes superiores às concentrações 
séricas de TgAb, enquanto apenas 27 doentes apresentavam concentrações séricas de 
TgAb 10 vezes superiores às concentrações séricas de TPOAb. 
Na última consulta, 30.1% (n = 104) dos doentes apresentavam concentrações 
séricas de TPOAb superiores às concentrações séricas de TgAb, 28.9% (n = 100) dos 
doentes apresentavam concentrações séricas de TgAb superiores às concentrações 
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séricas de TPOAb e apenas 5.9% (n = 20) apresentavam concentrações iguais de ambos 
anticorpos (n em falta = 119). Para os doentes com concentrações séricas de TPOAb 
superiores, o tempo médio de doença foi 9 ± 7 anos. Para os doentes com concentrações 
séricas de TgAb superiores, o tempo médio de doença foi 10 ± 8 anos. 42 doentes 
apresentavam concentrações séricas de TPOAb 10 vezes superiores às concentrações 
séricas de TgAb, enquanto apenas 22 doentes apresentavam concentrações séricas de 
TgAb 10 vezes superiores às concentrações séricas de TPOAb. 
3. Diferença entre a Função e Anticorpos Tiroideus da Primeira e Última Consultas 
Os níveis de TSH, T3, T4 e TPOAb sofreram um redução significativa entre as 
primeira e última consultas, (z = -2.748, n = 242, p = 0.006; z = -8.859, n = 237, p < 
0.001; z = -2.091; n = 235, p = 0.037; z = -5.706, n = 230, p < 0.001; respetivamente), 
como representado no Anexo 16 e ilustrado na Figure 1a, 1b, 1c, 1f. 
Todavia, os níveis de fT4 aumentaram significativamente entre as primeira e 
última consultas, (z = - 3.362, n = 221, p = 0.01), como representado no Anexo 16 e 
ilustrado na Figura 1d. 
Não se observou uma diferença estatisticamente significativa entre consultas 
para a Tg e TgAb, apesar de os seus níveis terem diminuído (Anexo 16 e Figura 1e, 1g). 
4. Influência dos Anticorpos Antitiroideus sobre as Outras Variáveis Tiroideias na 
Ausência de Terapêutica 
4.1 Primeira Consulta 
Na primeira consulta dos doentes não tratados, relata-se uma correlação positiva 
significativa, mas modesta, entre os níveis séricos de TPOAb e TgAb (r = 0.275, n = 
170, p < 0.001), como ilustrado no Anexo 17. O aumento dos níveis séricos de TPOAb 
correlacionou-se com aumento dos níveis séricos de TgAb. 
Verificou-se uma correlação positiva significativa, mas modesta, entre os níveis 
séricos de TPOAb e os níveis séricos de TSH (r = 0.212, n = 169, p = 0.006), como 
ilustrado no Anexo 17. O aumento dos níveis séricos de TPOAb correlacionou-se com 
aumento dos níveis séricos de TSH. 
Observou-se uma correlação negativa significativa, mas modesta, entre os níveis 
séricos de TPOAb e os níveis séricos de fT4 (r = -0.194, n = 158, p = 0.014), como 
ilustrado no Anexo 17. O aumento dos níveis séricos de TPOAb correlacionou-se com 
redução dos níveis séricos de fT4. 
O TPOAb sérico não se correlacionou com os níveis séricos de T3, T4 ou Tg. 
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Observou-se uma correlação negativa significativa, mas modesta, entre os níveis 
séricos de TgAb e os níveis séricos de Tg (r = -0.319, n = 80, p = 0.004), como ilustrado 
no Anexo 18. O aumento dos níveis séricos de TgAb correlacionou-se com redução dos 
níveis séricos de Tg. 
O TgAb sérico não se correlacionou com os níveis séricos de TSH, T3, T4 ou 
fT4. 
4.2 Última Consulta 
Na última consulta dos doentes não tratados, o TPOAb sérico não se 
correlacionou com os níveis séricos de TgAb, TSH, T3, T4, fT4 ou Tg. 
Observou-se uma correlação negativa significativa, mas modesta, entre os níveis 
séricos de TgAb e os níveis séricos de Tg (r = -0.370, n = 46, p = 0.011), como ilustrado 
no Anexo 20. O aumento dos níveis séricos de TgAb correlacionou-se com redução dos 
níveis séricos de Tg. 
O TgAb sérico não se correlacionou com os níveis séricos de TSH, T3, T4 ou 
fT4. 
5. Subgrupo da População em Estudo com Tg Positiva e TgAb Positivos 
Na primeira consulta, 13 doentes apresentavam Tg positiva e TgAb positivos. 
Todos os doentes eram do sexo feminino. Os dados descritivos deste subgrupo 
populacional estão demonstrados na Tabela 3. 
Na última consulta, 10 doentes apresentavam Tg positiva e TgAb positivos. 
Todos os doentes eram do sexo feminino. Os dados descritivos deste subgrupo 
populacional estão demonstrados na Tabela 4. 
 
Discussão 
Apesar de a doença tiroideia autoimune constituir uma doença autoimune 
prevalecente e a causa mais comum de hipotiroidismo primário em populações sem 
carência de iodo, os papéis funcional e clínico dos anticorpos anti-tiroideus permanecem 
por esclarecer. 
Enquanto que o TPOAb é considerado o marcador serológico mais preciso para 
autoimunidade tiroideia, com consequências patogénicas demonstradas, o TgAb é 
menos útil e possui um papel mais incerto. 
A determinação de possíveis relações entre TPOAb e TgAb e as hormonas 
tiroideias bem como as respetivas evoluções temporais seria útil para esclarecer o papel 
patogénico dos anticorpos na doença tiroideia autoimune. 
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1. Perfil da População em Estudo 
No presente estudo, os doentes eram principalmente do sexo feminino e meia 
idade, o que é consistente com a distribuição demográfica habitualmente descrita para 
doença tiroideia autoimune. A idade avançada e o sexo feminino são fatores de risco 
cruciais para o desenvolvimento de tiroidite de Hashimoto. Adicionalmente, a 
frequência de positividade TPOAb e TgAb aumenta com a idade nas mulheres. A 
preponderância feminina deve-se provavelmente aos efeitos das hormonas sexuais na 
resposta imune, mas uma inativação enviesada do cromossoma X e microquimerismo 
fetal foram propostos como mecanismos alternativos. 
Uma longa duração de doença na tiroidite de Hashimoto, como na nossa 
população em estudo, é um achado comum, já que o curso inicial da doença é 
frequentemente silencioso e o diagnóstico formal é realizado anos após o início da 
doença. 73% dos doentes tinham disfunção tiroideia à apresentação, mas a maioria 
estava sob terapêutica com levotiroxina. Não obstante, uma apresentação eutiróide ou 
hipotiroidismo subclínico na tiroidite de Hashimoto não são incomuns, demonstrando a 
natureza indolente do processo autoimune subjacente e a capacidade de compensação da 
TSH. 
2. Relação entre TPOAb e TgAb 
A prevalência de autoanticorpos na tiroidite de Hashimoto é quase 100% para 
TPOAb e 60–80% para TgAb. Neste estudo, todos os doentes eram positivos para um 
ou o outro anticorpo, uma vez que a positividade de anticorpos for um dos critérios de 
seleção da população em estudo. Os TPOAb foram mais frequentemente mesuráveis do 
que os TgAb (66,8% versus 46% na primeira consulta; 41,3% versus 31,8% na última 
consulta; respetivamente), com diferença estatisticamente significativa, o que é 
consistente com o estado de anticorpos anti-tiroideus observado em estudos anteriores. 
Em comparação com os TgAb, os TPOAb demonstram maiores concentrações 
séricas na doença tiroideia autoimune. Globalmente, as concentrações séricas de 
TPOAb foram mais elevadas que as concentrações séricas de TgAb, na nossa população 
em estudo, mas esta diferença foi apenas estatisticamente significativa na primeira 
consulta. Contudo, quando se considera apenas o valor qualitativo dos anticorpos, a 
proporção de casos positivos para TPOAb foi significativamente mais elevada que a 
proporção de casos positivos para TgAb em ambas consultas. Adicionalmente, a grande 
variabilidade de valores quantitativos obtidos para TPOAb e TgAb foi também 
documentada em estudos diferentes. 
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Todavia, quase um terço dos doentes em ambas visitas apresentavam 
concentrações séricas de TgAb mais elevadas que as concentrações séricas de TPOAb. 
Como tal, alguns doentes produziam preferencialmente TPOAb, enquanto que outros 
principalmente desenvolviam TgAb. Carlé et al. não encontrou diferenças referentes às 
características dos doentes (sexo, idade, estado de iodo, bócio) entre estes dois 
subgrupos, na população do seu estudo, tendo proposto que um fenómeno aleatório 
seria responsável por qual anticorpo é predominantemente gerado. 
Descrevemos uma correlação significativa positiva, mas apenas modesta, entre 
os dois autoanticorpos (TPOAb and TgAb), na nossa população em estudo de tiroidite 
de Hashimoto, um achado semelhante a outros estudos. 
É legítimo questionar se a natureza fraca da correlação entre TPOAb e TgAb e a 
ocorrência de produção predominante de um anticorpo ou outro estão relacionadas. 
Caturegli et al. argumentaram que esta correlação fraca entre os anticorpos 
sugeria que seriam expressos em fases diferentes da doença, com os TgAb precedendo o 
aparecimento de TPOAb. Um mecanismo de escalação imune for proposto, onde os 
TgAb estariam presentes na instalação da doença, na forma de uma resposta inicial do 
sistema imune inato, e os TPOAb representariam a conseguinte resposta imunitária 
adaptativa. De facto, isto foi demonstrado em modelos de ratos. Nos doentes humanos, 
o diagnóstico de tiroidite de Hashimoto é realizado anos após a instalação da doença, 
pelo que se espera uma maior prevalência e títulos de TPOAb. 
Seria possível que este mecanismo explicasse, simultaneamente, a correlação 
fraca entre os anticorpos e o motivo pelo qual alguns doentes desenvolvem 
principalmente TgAb em vez de TPOAb? Adequando-se ao modelo de escalação imune, 
doentes que expressassem principalmente TgAb estariam em fases precoces da doença. 
Curiosamente, Carlé et al. observou que os valores TSH sérico tendiam a ser mais 
reduzidos nos doentes predominantemente positivos para TgAb, apesar de não ser uma 
diferença estatisticamente significativa. Os níveis séricos de TSH aumentam com a 
progressão da doença, sendo expectáveis níveis mais elevados de TSH, tal como níveis 
mais elevados de TPOAb, nas fases mais avançadas de doença. 
Uma questão permanece por esclarecer: por que razão esta correlação entre 
TPOAb e TgAb não foi encontrada na última consulta? Se a última consulta representar 
uma fase mais tardia da doença, de acordo com a hipótese de escalação imune, a 
discrepância entre a produção e níveis séricos de TPOAb e TgAb seria ainda mais 
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desviada para os TPOAb nesta fase. Consequentemente, uma correlação seria menos 
provável nas fases mais avançadas da doença. 
27 e 22 doentes apresentaram concentrações séricas de TgAb 10 vezes mais 
elevadas que as concentrações séricas de TgAb nas primeira e última consultas, 
respetivamente. É questionável se esta disparidade considerável poderia enquadrar-se no 
modelo de escalação autoimune ou se este subgrupo de doentes representa uma situação 
clínica diferente, como uma resposta imune específica despoletada pela neoplasia 
diferenciada da tiróide. 
3. Diferenças entre os Anticorpos Anti-Tiroideus e Função Tiroideia entre Consultas 
No presente estudo, os níveis séricos de TSH, T3, T4 e TPOAb diminuíram e os 
níveis séricos de fT4 aumentaram entre consultas. Os níveis séricos de TgAb e Tg 
diminuírem entre consultas, mas tal diferença não foi estatisticamente significativa. Não 
obstante, o número de casos positivos de TgAb diminui significativamente entre 
consultas. O mesmo se aplica aos casos positivos de TPOAb. Equacionamos duas 
razões possíveis para explicar estes achados. 
Em primeiro lugar, não podemos ignorar a potencial influência da levotiroxina, 
na medida em que a percentagem de doentes sob terapêutica com levotiroxina neste 
estudo aumentou de 49% para 73% entre consultas. Uma revisão sistemática e meta 
análise recente estudou 25 estudos clínicos randomizados, sobre a eficácia clínica da 
levotiroxina no tratamento de hipotiroidismo manifesto e subclínico, tendo descrito, ao 
comparar o grupo sob levotiroxina e o grupo placebo: uma redução significativa de TSH 
e aumento significativo de fT4 tanto no hipotiroidismo manifesto como no subclínico; e 
ausência de diferença de T3 no hipotiroidismo manifesto, mas uma redução significativa 
de T3 no hipotiroidismo subclínico. A terapêutica de substituição hormonal tiroideia 
alcança níveis normais de TSH ao corrigir a sobre-estimulação do eixo hipotálamo-
hipófise-tiróide. Os níveis reduzidos de TSH poderiam contribuir para a redução de T3, 
T4 e Tg, ao diminuir a estimulação da glândula tiroideia. Estudos anteriores 
descreveram diminuição dos níveis de TPOAb após terapêutica com levotiroxina. 
Chiovato et al. argumentou que tal diminuição não se poderia dever a flutuações 
espontâneas do anticorpo, uma vez que não observou essa mesma diminuição nos 
doentes eutirodeus com tiroidite de Hashimoto. A expressão genética e atividade da 
TPO bem como a localização da TPO na membrana dos tirócitos é um fenómeno 
estimulado pela TSH. Tal como discutido por outros autores, a supressão da TSH pela 
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levotiroxina poderia causar uma redução da expressão de TPO, diminuindo a resposta 
autoimune e os níveis de TPOAb. 
Em segundo lugar, devemos considerar a história natural da tiroidite de 
Hashimoto. O processo destrutivo da tiroidite linfocítica crónica engloba a atrofia do 
epitélio folicular a par de graus variáveis de fibrose da glândula tiroideia. A atrofia 
folicular e perda de colóide poderá levar à perda gradual da hormonogénese tiroideia, 
sendo responsável pela redução de T3, T4 e Tg. À semelhança do que ocorre na 
neoplasia diferenciada da tiróide, a redução dos autoanticorpos tiroideus poderia ser 
explicada pela atrofia e fibrose da glândula tiroideia. Na neoplasia diferenciada da 
tiróide, a eliminação completa do tecido tiroideu, por tiroidectomia total e terapêutica de 
radioablação, determina o desaparecimento de anticorpos anti-tiroideus da circulação, 
na ausência de doença persistente ou recorrente, com um tempo de desaparecimento 
médio de 3 anos para os TgAb e 6.3 anos para os TPOAb. Colocamos a hipótese de que 
a atrofia da glândula tiroideia poderá resultar na depleção parcial de autoantigénios 
tiroideus e linfócitos B intra-tiroideus, removendo parcialmente o estímulo e principais 
fontes de produção de anticorpos anti-tiroideus. 
4. Influência dos Anticorpos Anti-Tiroideus sob Outras Variáveis 
Encontrámos uma correlação significativa positiva, mas modesta, entre os níveis 
séricos de TPOAb e TSH na primeira consulta, mas não na última consulta. Esta 
correlação foi encontrada em doentes hipotiroideus e eutiroideus, noutros estudos. A 
relação entre a TPO e a TSH realçada acima pode explicar tal associação. 
Os níveis de TPOAb correlacionam-se negativamente com os níveis de fT4 na 
primeira consulta. O TPOAb tem potencial patogénico na tiroidite de Hashimoto, mas a 
sua tradução in vivo e a importância que assume no processo autoimune global é dúbio. 
A correlação negativa entre TPOAb e fT4 poderia clarificar a correlação positiva entre 
TPOAb e TSH. Se os TPOAb diminuem a fT4, tal resultaria num aumento 
compensatório de TSH. 
Os TPOAb não se correlacionam com T3 e T4, o que está em desacordo com 
outros estudos na literatura. A relação inconsistente entre TPOAb e T3 e T4 poderá ser 
causada pela ligação das hormonas tiroideias às proteínas plasmáticas de transporte. 
Não houve correlação entre TgAb e TSH, apesar de uma produção anormal de 
TgAb associar-se a níveis de TSH anormais. 
Os níveis séricos de TgAb não se correlacionaram com T3, T4 ou fT4. Os TgAb 
não fixam complemento nem causam destruição das células tiroideias. 
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Previsivelmente, verificámos uma correlação significativa negativa, mas fraca, 
entre os níveis séricos de TgAb e Tg, em ambas consultas. Uma vez que os TgAb são 
direcionados contra a Tg, esta correlação é expectável. A correlação é fraca porque a 
interferência dos TgAb anula as medições de Tg e não é concentração-dependente. 
5. Conclusão 
As alterações nos anticorpos anti-tiroideus e função tiroideia observadas no 
seguimento destes doentes mostra que a tiroidite de Hashimoto não é uma doença 
imutável. A correlação entre TPOAb e fT4 e TSH poderá sugerir a importância deste 
anticorpo na tiroidite de Hashimoto. As diferenças na expressão de TPOAb e TgAb em 
diferentes subgrupos de doentes poderão refletir a evolução natural da tiroidite de 
















































This page intentionally left blank 
